Evidence map›Paper›PMID 26600217›Full record

ReviewGastroenterology clinics of North America2015

Immunopathogenesis of Hepatitis C Virus Infection.

David E Kaplan

Open access · greenAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Gastroenterology clinics of North America, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

David E KaplanMedicine and Research Services, Corporal Michael J. Crescenz VA Medical Center, 3900 Woodland Avenue, Philadelphia, PA 19104, USA; Division of Gastroenterology, Department of Medicine, University of Pennsylvania, BRB II/III, 9th Floor, 415 Curie Boulevard, Philadelphia, PA 19104, USA. Electronic address: dakaplan@mail.med.upenn.edu.
University of Pennsylvania · US

Funding

TRANSGENIC AND CHIMERIC MOUSE COREP30DK050306 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI REBECCA G WELLS · 1997 to 2026
$32.5M
Tumor antigen-specific T-cells and hepatocellular carcinomaR01CA166111 · NCI · UNIVERSITY OF PENNSYLVANIA · PI KAPLAN, DAVID E · 2013 to 2016
$1.3M
B-Cell Dysregulation in Cirrhosis due to Chronic Hepatitis C InfectionI01CX000981 · VA · PHILADELPHIA VA MEDICAL CENTER · PI KAPLAN, DAVID E · 2014 to 2019
–
CSRD VA I01 CX000981NCI NIH HHS R01 CA166111NIDDK NIH HHS L30 DK069063NIDDK NIH HHS P30 DK050306
6 · The paper itself

Abstract

Despite advances in therapy, hepatitis C virus infection remains a major global health issue with 3 to 4 million incident cases and 170 million prevalent chronic infections. Complex, partially understood, host-virus interactions determine whether an acute infection with hepatitis C resolves, as occurs in approximately 30% of cases, or generates a persistent hepatic infection, as occurs in the remainder. Once chronic infection is established, the velocity of hepatocyte injury and resultant fibrosis is significantly modulated by immunologic as well as environmental factors. Immunomodulation has been the backbone of antiviral therapy despite poor understanding of its mechanism of action.

Indexed as

Adaptive ImmunityImmunity, InnateHepatitis C, ChronicHumansAdaptive immunityHepatitis CHumanInnate immunityRegulatory T cells

Identifiers

PMID26600217
PMCPMC4660249
OpenAlexW1198831805

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.